{
    "clinical_study": {
        "@rank": "82525", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die. Combining more than one drug may kill more tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of dexamethasone plus paclitaxel and\n      gemcitabine in treating patients with platinum-resistant recurrent ovarian cancer."
        }, 
        "brief_title": "Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer", 
        "completion_date": {
            "#text": "February 2004", 
            "@type": "Actual"
        }, 
        "condition": "Ovarian Cancer", 
        "condition_browse": {
            "mesh_term": "Ovarian Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the response rate, progression time, and survival of patients with\n           platinum-resistant ovarian cancer treated with weekly paclitaxel and gemcitabine.\n\n        -  Determine the toxic effects of this regimen in these patients.\n\n        -  Evaluate the toxic effects and safety profile of premedication with steroids with this\n           regimen in these patients.\n\n      OUTLINE: Patients are stratified according to prior treatment with paclitaxel (none or\n      relapse more than 6 months after paclitaxel versus progressive disease or relapse less than\n      6 months after paclitaxel).\n\n      Patients receive dexamethasone IV, then paclitaxel IV followed by gemcitabine IV, for 3\n      consecutive weeks on days 1, 8, and 15. Treatment is continued every 4 weeks in the absence\n      of disease progression or unacceptable toxicity.\n\n      All patients are followed until death.\n\n      PROJECTED ACCRUAL: Approximately 18-35 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed recurrent ovarian epithelial cancer\n\n          -  Platinum resistant disease defined as:\n\n               -  Progression during the most recent platinum-based chemotherapy OR\n\n               -  Relapse less than 6 months after platinum-based chemotherapy\n\n          -  Measurable or evaluable disease\n\n               -  Elevated CA-125 only allowed\n\n               -  Positive cytology only not eligible\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  SWOG 0-2\n\n        Hematopoietic:\n\n          -  Granulocyte count at least 1,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin less than 2 times upper limit of normal (ULN)\n\n          -  AST less than 3 times ULN\n\n        Renal:\n\n          -  Creatinine no greater than 2 mg/dL\n\n        Neurologic:\n\n          -  No peripheral neuropathy greater than grade 2\n\n        Other:\n\n          -  No other serious medical illness or psychiatric conditions.\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No concurrent hematopoietic growth factors\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n          -  No prior gemcitabine\n\n          -  No prior paclitaxel administered weekly\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  Not specified\n\n        Surgery:\n\n          -  Not specified\n\n        Other:\n\n          -  Recovered from acute toxic effects secondary to prior therapy"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003449", 
            "org_study_id": "CDR0000066478 (5O-98-1)", 
            "secondary_id": [
                "LAC-USC-5O981", 
                "NCI-G98-1460"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "dexamethasone", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "gemcitabine hydrochloride", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "paclitaxel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "Gemcitabine", 
                "Paclitaxel", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "recurrent ovarian epithelial cancer", 
        "lastchanged_date": "May 20, 2014", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/LAC-USC-5O981"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90033-0804"
                }, 
                "name": "USC/Norris Comprehensive Cancer Center and Hospital"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Study of Weekly Paclitaxel and Gemcitabine in Platinum-Resistant Ovarian Cancer", 
        "overall_official": {
            "affiliation": "University of Southern California", 
            "last_name": "Agustin Garcia, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2002", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003449"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Southern California", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Southern California", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 1998", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }, 
    "geocoordinates": {
        "USC/Norris Comprehensive Cancer Center and Hospital": "34.052 -118.244"
    }
}